Distinguishing HER2 receptor expression status on the surface of breast cancer tumor cells as simply positive or negative is now proving insufficient. Ultimately, it can lead to the non-administration of effective targeted therapy. What do we actually know about the “gray zone” between HER2 positivity and negativity?
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
